Glaxo, Genmab say disappointed with study of lymphoma treatment
May 19 (Reuters) - GlaxoSmithKline and Danish biotech company Genmab said disappointing results from a study on treating relapsed lymphoma with their ofatumumab drug meant it was unlikely they would seek its regulatory approval. A head-to-head phase III study of ofatumumab and another drug
